Progression of Late-Onset Stargardt Disease

URN to cite this document:: urn:nbn:de:bvb:355-epub-351128
DOI to cite this document:: 10.5283/epub.35112

Lambertus, Stanley

; Lindner, Moritz

; Bax, Nathalie M. ; Mauschitz, Matthias M. ; Nadal, Jennifer ; Schmid, Matthias

; Schmitz-Valckenberg, Steffen ; den Hollander, Anneke I. ; Weber, Bernhard H. F.

; Holz, Frank G. ; van der Wilt, Gert Jan ; Fleckenstein, Monika

; Hoyng, Carel B.

Preview

License: Creative Commons Attribution Non-commercial No Derivatives 4.0
PDF - Published Version
(842kB)

Date of publication of this fulltext: 30 Jan 2017 12:39

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

PURPOSE. Identification of sensitive biomarkers is essential to determine potential effects of emerging therapeutic trials for Stargardt disease. This study aimed to describe the natural history of late-onset Stargardt, and demonstrates the accuracy of retinal pigment epithelium (RPE) atrophy progression as an outcome measure. METHODS. We performed a retrospective cohort study collecting ...